GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

ABP-671

Company
Atom Therapeutics Co., Ltd
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for ABP-671 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07367971

    Drug-Drug Interaction Study of ABP-671 in Gout Patients

    Not yet reported Atom Therapeutics Co., Ltd 20 participants Est. completion 2026-08-31 1 site Stand-alone
    Other conditions: Gout Chronic, Gout, DDI (Drug-Drug Interaction)
    View official trial listing →
  • Completed NCT NCT03906006

    A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671 in Healthy Subjects

    Not yet reported Atom Therapeutics Co., Ltd 32 participants Est. completion 2019-06-20 1 site Stand-alone
    Other conditions: Gout, Hyperuricemia
    View official trial listing →
  • Completed NCT NCT04060173

    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671

    Not yet reported Atom Therapeutics Co., Ltd 27 participants Est. completion 2020-02-07 1 site Stand-alone
    Other conditions: Hyperuricemia, Gout
    View official trial listing →
  • Completed NCT NCT04303039

    Study to Investigate the Effects of Food on Relative Bioavailability of ABP-671 Tablets in Healthy Subjects

    Not yet reported Atom Therapeutics Co., Ltd 12 participants Est. completion 2020-06-19 1 site Stand-alone
    Other conditions: Gout, Food-drug Interaction
    View official trial listing →
  • Completed NCT NCT04638543

    A Study to Assess the Efficacy, Safety, and Pharmacokinetics of ABP-671 in Patients With Gout or Hyperuricemia

    Not yet reported Atom Therapeutics Co., Ltd 60 participants Est. completion 2021-10-26 5 sites Stand-alone
    Other conditions: Gout, Hyperuricemia
    View official trial listing →
  • Completed NCT NCT05818085

    Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

    Not yet reported, Not yet reported Atom Therapeutics Co., Ltd 300 participants Est. completion 2025-03-30 57 sites Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Terminated NCT NCT06276556

    Extension Study of ABP-671 in Participants With Gout

    Not yet reported, Not yet reported Atom Therapeutics Co., Ltd 43 participants Est. completion 2024-09-05 54 sites Stand-alone
    Other conditions: Gout
    View official trial listing →
  • Not yet recruiting NCT NCT07323095

    Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia

    Not yet reported Atom Therapeutics Co., Ltd 80 participants Est. completion 2028-01-31 10 sites Stand-alone
    Chronic kidney disease
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.